Imaging VEGF receptor expression to identify accelerated atherosclerosis by unknown
Tekabe et al. EJNMMI Research 2014, 4:41
http://www.ejnmmires.com/content/4/1/41ORIGINAL RESEARCH Open AccessImaging VEGF receptor expression to identify
accelerated atherosclerosis
Yared Tekabe1, Maria Kollaros1, Adam Zerihoun1, Geping Zhang1, Marina V Backer2, Joseph M Backer2
and Lynne L Johnson1*Abstract
Background: The biology of the vulnerable plaque includes increased inflammation and rapid growth of vasa
vasorum, processes that are associated with enhanced vascular endothelial growth factor (VEGF)/ imaging receptors
for VEGF (VEGFR) signaling and are accelerated in diabetes. This study was designed to test the hypothesis that
VEGFRs in atherosclerotic plaques with a SPECT tracer scVEGF-PEG-DOTA/99mTc (scV/Tc) can identify accelerated
atherosclerosis in diabetes.
Methods: Male apolipoprotein E null (ApoE−/−) mice (6 weeks of age) were made diabetic (n = 10) or left as
non-diabetic (n = 13). At 26 to 28 weeks of age, 5 non-diabetic mice were injected with functionally inactivated
scV/Tc (in-scV/Tc) that does not bind to VEGF receptors, while 8 non-diabetic and 10 diabetic mice were injected
with scV/Tc. After blood pool clearance, at 3 to 4 h post-injection, mice were injected with CT contrast agent and
underwent SPECT/CT imaging. From the scans, regions of interest (ROI) were drawn on serial transverse sections
comprising the proximal aorta and the percentage of injected dose (%ID) in ROIs was calculated. At the completion
of imaging, mice were euthanized, proximal aorta explanted for gamma well counting to determine the percentage
of injected dose per gram (%ID/g) uptake and immunohistochemical characterization.
Results: The uptake of scV/Tc in the proximal aorta, calculated from SPECT/CT co-registered scans as %ID, was
significantly higher in the diabetic mice (0.036 ± 0.017%ID) compared to non-diabetic mice (0.017 ± 0.005%ID;
P < 0.01), as was uptake measured as %ID/g in harvested aorta, 1.81 ± 0.50%ID/g in the diabetic group vs.
0.98 ± 0.25%ID/g in the non-diabetic group (P < 0.01). The nonspecific uptake of in-scV/Tc in proximal aorta
was significantly lower than the uptake of functionally active scV/Tc. Immunostaining of the atherosclerotic lesions
showed higher expression of VEGFR-1 and VEGFR-2 in the diabetic mice.
Conclusion: These initial results suggest that imaging VEGFR with scV/Tc shows promise as a non-invasive approach
to identify accelerated atherosclerosis.
Keywords: Vascular endothelial growth factor; Atherosclerosis; Molecular imagingBackground
Rupture of an atherosclerotic plaque in the coronary or
carotid arteries can lead to sudden and lethal events. A
non-invasive imaging approach for detection of athero-
sclerotic plaques that are prone to rupture would allow
for timely preventive treatment and therefore would
have a significant clinical impact. In addition to targeting
plaque inflammation with 18FDG, a number of specific* Correspondence: lj2129@cumc.columbia.edu
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in any medium, provided the original work is pbiomarkers, such as P-selectin, VCAM, metallopro-
teinases, and integrins have been investigated for im-
aging in mouse models and in human endarterectomy
specimens [1-7].
Key characteristics of vulnerable plaques include rapid
plaque growth accompanied by outward vessel remode-
ling without increases in luminal narrowing, increased
inflammation, and rapid growth of both the hypoxic
central core and adventitial vasa vasorum [8]. As expec-
ted for pathologies involving inflammation and hypoxia,
plaque development is associated with increase in the
expression of vascular endothelial growth factor (VEGF)an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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phages, and other plaque constituent cells. VEGF/VEGFR
signaling has been implicated in the development of ath-
erosclerosis and plaque vulnerability [8-14] particularly in
association with diabetes [15-17].
Since the prevalence of VEGFRs, specifically VEGFR-1
and VEGFR-2, in vulnerable plaques is increased rela-
tive to more stable ones, we hypothesized that VEGFR
imaging might provide a useful biomarker for asses-
sing plaque vulnerability. To test this hypothesis we used
SPECT molecular imaging for quantifying VEGFR preva-
lence in plaques in apolipoprotein null (ApoE−/−) mice in
which complex plaque development is accelerated by in-
duction of diabetes.
For VEGFR imaging, we employed previously described
scVEGF-PEG-DOTA/99mTc SPECT tracer, (scV/Tc), based
on an engineered single-chain (sc) recombinant VEGF,
site-specifically derivatized with PEGylated chelator DOTA
[18-21]. scVEGF-PEG-DOTA conjugate appears to be
a versatile platform for the developing of VEGFR-
targeting imaging tracers and radiopharmaceuticals.
Various scVEGF-based imaging tracers retain nano-
molar affinity to VEGFRs, are readily internalized upon
binding to the receptors, and reliably detect VEGFR in
animal models of cancer [22,23], aortic aneurism [24],
graft atherosclerosis [25], and inflammation [26,27]. Up-
take of scVEGF/Cy5.5 by NIRF imaging of in human ca-
rotid endarterectomy specimens localized to expression of
VEGFR1 and VEGFR2 and histological characteristics of
intraplaque capillary density and infiltrating macrophages
[28]. Importantly, the nonspecific uptake of scVEGF-
based tracers is evaluated using corresponding tracers
based on functionally inactivated scVEGF that does
not bind to VEGFRs [19].
Methods
Animals
All animal studies were performed with the approval of
the Institutional Animal Care and Use Committee of
Columbia University. Male C57BL/6 mice and ApoE−/−
mice with the genetic background of C57BL/6 mice were
purchased from The Jackson Laboratories (Bar Harbor,
ME, USA).
Induction of diabetes
At 6 weeks of age, mice were made diabetic via 5 con-
secutive daily doses of streptozotocin (Sigma, 50 mg/kg
in citrate buffer, pH 4.5; St. Louis, MO, USA). Blood glu-
cose levels were monitored weekly via tail vein sampling
using blood glucose monitor (FreeStyle Lite, Abbott,
North Chicago, IL, USA). The mean blood glucose level
for the duration for diabetic mice was 309 ± 39 mg/dL.
Animals were studied at 26 to 28 weeks of age. On ar-
rival, all of the apoE−/−mice had similar weights, but bythe time of study, the diabetic mice were smaller than
the non-diabetic mice with average weights of 23.1 ± 1.2
and 30.7 ± 1.1 g (P = 0.0001).
Radiotracer preparation
scV/Tc is based on scVEGF protein which combines
two 3 to 112 fragments of human VEGF fused head to
tail and is expressed with an N-terminal 15-aa cysteine-
containing tag (Cys-tag) for site-specific conjugation
[19]. scVEGF-PEG-DOTA and its inactivated analog that
lacks VEGFR-binding ability were prepared as described
[19]. Briefly, scVEGF was site-specifically derivatized
on C4 in Cys-tag with radionuclide chelator 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
via 3.4 kDa PEGylated linker. The inactivated VEGF-
PEG-DOTA was prepared by biotinylation of 10 to 12
lysine ε amino groups in scVEGF moiety. For 99mTc label-
ing, lyophilized 0.15 mg scVEGF-PEG-DOTA (approxi-
mately 5 nmol) was reconstituted with 75 μl of 0.1 M
NaOAc buffer (pH 5.5) and added to 30 to 40 mCi (1,110
to 1,480 MBq) of 99mTc. The mixture was purged with N2
for 2 min followed by addition of 50 μg of tin-tricine in
450 μl of deionized water, briefly purged with N2 and in-
cubated for 20 min at 55°C. Free 99mTc was separated on
PD-10 column (Pharmacia) equilibrated with PBS/0.1%
BSA. Fractions (0.5 ml) containing the tracer in the
void volume were pooled. The radiochemical purity of
scV/Tc was 97% ± 1.6% with the specific activity of 109 ±
11 μCi/μg. The inactivated scVEGF-PEG-DOTA was
similarly labeled with 99mTc and the resulting tracer
was named in-scV/Tc.
Blood pool clearance and biodistribution
Blood pool clearance was measured in 3 C57BL/6 mice
and 3 ApoE−/−diabetic mice. Blood samples were taken
by tail vein knicking at 5, 10, 30, 60, 90, 200, 250, and
350 min. Biodistribution of scV/Tc in non-target organs
was analyzed in diabetic and non-diabetic mice after
imaging. At necropsy, organs were removed, weighed,
and counted in the well counter (Wallac Wizard 1470,
PerkinElmer, Waltham, MA, USA).
SPECT/CT imaging
Non-diabetic ApoE−/− mice (n = 8) and diabetic ApoE−/−
mice (n = 10) mice were anesthetized with isofluorane
(4% to induce, 1% to maintain) and injected with scV/Tc
0.38 ± 0.08 mCi (14.06 ± 2.92 MBq) via femoral vein
catheter. To assess nonspecific (non VEGFR-mediated)
tracer uptake, a separate group of non-diabetic ApoE−/−
mice (n = 5) were injected with in-scV/Tc (tracer con-
trol). To assess uptake of tracer in non-diseased mice, 2
C57BL/6 mice were injected with scV/Tc (disease control).
Three to 4 h after tracer injection (blood pool clearance),
all mice were re-anesthetized and injected with 150 to
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Biomedical, Ottawa, Canada) and immediately under-
went SPECT/CT imaging on nanoSPECT/CT system
(Bioscan, Washington DC, USA).
CT images were acquired with an integrated CT scan-
ner using an X-ray tube at 45 kVp and an exposure time
of 1,000 ms per view. The helical SPECT scans were ac-
quired using dual-headed detectors each outfitted with
collimators with nine pinholes. Each pinhole had a dia-
meter of 1.4 mm with each collimator providing a trans-
axial field-of-view (FOV) of 30 mm and an axial FOV of
16 mm, extendable through helical scanning to 270 mm.
SPECT data were acquired with the following parame-
ters: step and shoot rotation, 30° step in 360° rotation
using 24 projections, 60 s per projection, 256 × 256 frame
size with 1.0 mm pixels, and 140 keV with 10% energy
window. The obtained projection data were recons-
tructed by ordered subset expectation-maximization
algorithm with subset and iteration number set to 16
and 8, respectively, and a voxel size of 300 μm and
SPECT and CT datasets fused. At the end of imaging,
mice were euthanized by an intraperitoneal injection
of pentobarbital (100 mg/kg).
Image analyses
The scans were reconstructed and processed using
InVivoScope software (Invicro, Boston, MA, USA). Tracer
uptake identified as focal areas of activity in the ascending
aorta, arch, and brachiocephalic trunk were identified on
transverse sections by triangulating from coronal and/or
sagittal images and using contrast in the vessels on the
CTA for anatomical localization. Regions of interest
(ROIs) were drawn around all these areas of focal activity
and counts in the ROIs converted to mCi using a calibra-
tion algorithm and activity for all regions summed for the
total vascular tracer uptake (Figure 1). The summed ac-
tivity from the ascending aorta and arch (excluding the
brachiocephalic vessels) was correlated with ex vivo gam-
ma counting of the same tissue. To address whether
there were differences in blood pool activity betweencoronal
Figure 1 Method for ROI placement for quantification. Slices comprisin
projection, and an ROI is drawn around the uptake on the transverse proje
calibration standard that is loaded into the software.the diabetic and non-diabetic mice at the time of imaging,
ROIs were drawn in the center of the mid-LV cavity on
the transverse slice to measure activity (in mCi/mm3).
Ex vivo gamma well counting
The chest was opened and the proximal aorta and arch
and brachiocephalic vessels photographed in situ. Due
to time-consuming and technical challenges in dissecting
the brachiocephalic vessels, the proximal aorta and arch
showing plaque was dissected for correlation with ac-
tivity measured on scans for the same anatomical seg-
ments. The fragment were excised and washed in PBS
and weighed, and the radioactivity was counted in a
gamma well counter (Wallac Wizard 1470, PerkinElmer,
Waltham, MA, USA) and expressed as the percentage of
injected dose per gram (%ID/g) of tissue. Radiotracer accu-
mulation in non-target organs was determined similarly.
Histology and immunohistochemistry
The proximal aorta was harvested and fixed for 24 h in
formalin (10%) and paraffin-embedded. Tissue blocks were
sectioned (5-μm-thick) and stained with hematoxylin-
eosin (H&E) for morphological evaluation. Serial sections
(5-μm-thick) were deparaffinized in xylene, treated with
0.3% hydrogen peroxide for 20 min, followed by incuba-
tion in protein-free block (Dako, Carpinteria, CA, USA)
for 10 min to inhibit the nonspecific binding of the pri-
mary antibody. Sections were stained for macrophage
marker Mac-3 (RM0029-11H3, rat monoclonal antibody,
1:50 dilution, Santa Cruz Biotechnology, Dallas, TX,
USA), VEGFR-1 (rabbit monoclonal antibody, 1:100 dilu-
tion, Abcam, Cambridge, MA, USA), VEGFR-2 (rabbit
monoclonal antibody, 1:1,500 dilution, Cell Signaling
Technology, Beverly, MA, USA), and pan-endothelial cell
marker FVIII (rabbit polyclonal antibody, 1:250 dilution,
Dako, Carpinteria, CA, USA). Detection was performed
with HRP-conjugated respective secondary system fol-
lowed by diaminobenzidine (DAB substrate kit for perox-
idase, Vector Laboratories) and counterstaining with Gill's
hematoxylin solution.transverse
g the focal uptake (red color table) are identified on the coronal
ction. The counts in this region are converted to mCi using a
%
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Figure 2 Blood pool clearance and biodistribution of scV/Tc.
A. Blood pool clearance of scV/Tc in diabetic mice. Each time point
represents an average of three mice. B. Similar biodistribution of
scV/Tc in non-targeted organs in non-diabetic (blue bars) and diabetic
(red bars) mice. Bars represent mean ± SD. SI = small intestine.
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the arterial segments were performed using a Nikon mi-
croscope and Image-Pro Plus software (Media Cybernetics
Inc., Silver Spring, MD, USA). The plaque area in the
proximal aorta was measured as percent lesion area per
total area of the aorta. The positively stained area in the
lesion for each marker was calculated as percentage of im-
munostained area per total area of the vessel.
Immunofluorescence
To determine the cell types expressing VEGFR-1 and
VEGFR-2 in aortic lesions, dual fluorescent confocal mi-
croscopy studies were undertaken. Briefly, aortic sections
(5-μm-thick) were stained for VEGFR-1 and VEGFR
with the respective antibodies as described above. The
slides were then incubated with fluorescent tagged sec-
ondary antibodies (Texas Red) and co-stained with fluor-
escent antibodies for endothelial cells (anti-FVIII, 1:200;
fluorescein isothiocyanate) or macrophages (anti-Mac-3,
1:50; fluorescein isothiocyanate). The images were exa-
mined using confocal fluorescence microscope (Nikon,
Melville, NY, USA) and SPOT imaging software (Diagnostic
Instruments, Inc., Sterling Heights, MI, USA).
Statistical analysis
Data are reported as means ± standard deviation. Statis-
tical comparisons between the diabetic and non-diabetic
groups and between the inactivated and active tracers
were made using Welch's t test for groups of unequal
size and variance. Estimated power to detect an observed
twofold difference between groups of non-diabetic mice
imaged with inactivated tracer (n = 5) vs. active tracer
(n = 8) is better than 0.8; and between groups of non-
diabetic (n = 8) vs. diabetic mice (n = 10) imaged with
active tracer is better than 0.95. Differences between the
groups were considered significant at a value of P < 0.05.
Correlation for individual values for tracer uptake between
scan and well counting was assessed using the Pearson
product-moment correlation coefficient.
Results
Blood pool clearance and biodistribution
The clearance of scV/Tc in diabetic ApoE−/− and C57BL/6
mice was fitted to similar biexonential curves with t1/2 for
the first component of the curve 10 min and for the
second 150 min (Figure 2A for diabetic ApoE−/− mice).
The biodistribution of scV/Tc in non-target organs of
non-diabetic and diabetic ApoE−/− mice was found to
be similar, with highest uptake in the kidneys and liver
(Figure 2B).
Scans
Scans from diabetic and non-diabetic ApoE−/− mice showed
unequivocal uptake of scV/Tc in the proximal aorta andarch on the co-registered CT scan (Figure 3A,B,C,D
as representative scans) with tracer uptake extending
into the brachiocephalic vessels in the diabetic mice
(compare representative scan Figure 3A,B for diabetic
vs. Figure 3C,D for non-diabetic). ApoE−/− mice injected
with in-scV/Tc and C57BL/6 mice injected with scV/Tc
showed little or no tracer uptake in areas corresponding
to the location of the proximal aorta and arch on the co-
registered SPECT/CT scan (Figure 3E,F,G,H).
The blood pool activity levels determined from the
scans for the non-diabetic and diabetic mice were not
significantly different: 18.6 × 10–3 vs. 19.4 × 10−3 mCi/mm3
(P = 0.86).Lesion size
The mean cross-sectional area of the proximal aortic le-
sions, expressed as percent lesion area over total aortic
area, in the diabetic group (32.3% ± 6.05%) was signifi-
cantly larger than in the non-diabetic group receiving
scV/Tc (15.3 ± 4.3%; P < 0.01) The lesion size in the non-
diabetic ApoE−/− mice receiving the in-scV/Tc (12.0% ±
2.9%) was not statistically different from the non-diabetic
mice receiving scV/Tc.
ApoE-/- non-diabetic 
with in-scVTc
ApoE -/- diabetic 
with scVTc
Apo-/- non-diabetic 
with scVTc
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L liver
B
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C57BL/6 with scVTc 
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Figure 3 SPECT/CT imaging of atherosclerotic plaques in diabetic and non-diabetic ApoE−/− mice. Representative coronal (left) and
transverse (right) images obtained for diabetic ApoE−/− mouse (A, B), non-diabetic ApoE−/− mouse (C, D) injected with functionally active scV/Tc,
for non-diabetic ApoE−/− injected with functionally inactivated in-scV/Tc (E, F) for assessment of nonspecific, not VEGFR-mediated tracer uptake,
and C57BL/6 mouse (G, H) injected with scV/Tc for assessment of tracer uptake in non-atherosclerotic, non-diabetic mouse (disease control). The
CT contrast outlines the ventricular cavities and arterial vessels. Focal areas of scV/Tc uptake (in red) are found in the aortic arch and proximal
brachiocephalic branches in diabetic mice, but are localized mostly to the aortic root in the non-diabetic mouse, and yellow arrows indicate the
prominent areas of tracer uptake. No appreciable uptake of tracer localized to vascular territories was seen in the ApoE−/− mice injected with
in-scV/Tc or the C57BL/6 mice injected with scV/Tc.
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The average uptake of scV/Tc or in-scV/Tc in thorax
areas corresponding to the proximal aorta, arch, and
brachiocepahalic vessels was calculated from scans as %ID,
as described in Methods (Figure 4A). The average up-
take of scV/Tc in diabetic ApoE−/− mice was signifi-
cantly higher than in non-diabetic ApoE−/− mice (0.036 ±
0.017 vs. 0.017 ± 0.005%ID; P < 0.01) (Figure 4A). The non
VEGFR-mediated uptake of in-scV/Tc in ApoE−/− mice,
was significantly lower than that of functionally active
scV/Tc in age-matched ApoE−/− mice with similar size le-
sions (0.008 ± 0.005 vs. 0.017 ± 0.005%ID; P < 0.01).
These findings were confirmed by ex-vivo gamma well
counting of harvested fragments of aorta with the most
conspicuous plaques (Figure 4B). Uptake of scV/Tc calcu-
lated for these fragments as %ID/g in diabetic ApoE−/−
mice (1.81 ± 0.50%ID/g) was significantly higher than
that in the non-diabetic ApoE−/− group (0.9 ± 0.25%ID/g,P < 0.01). In fragments harvested from non-diabetic
ApoE−/− mice with similar extent of atherosclerosis the
nonspecific (non VEGFR-mediated) uptake of in-scV/Tc
(0.44 ± 0.12%ID/g) was significantly lower than scV/Tc
uptake (P < 0.01). Tracer uptake in the proximal aorta and
arch of each mouse, determined as %ID from scans, plot-
ted vs. %ID/g (well counter) determined for the same ana-
tomical aortic section in the same mouse correlated
significantly, (r = 0.75, P = 0.0017) (Figure 4C).
Histology and quantitative immunohistolchemistry
Lesions from the diabetic ApoE−/− mice showed complex
plaque anatomy with cholesterol clefts whereas lesions
from age-matched non-diabetic ApoE−/− mice were at an
earlier (fatty streak) stage. Immunostaining of serial sec-
tions through the plaque in the proximal aorta revealed
greater staining for VEGFR-1, VEGFR-2 in the diabetic
group than in the non-diabetic group, and this staining
AB
C
Figure 4 Quantitative analysis of tracer uptake. (A) Average %ID ±
standard deviation for uptake of functionally active scV/Tc in diabetic
(red bar), non-diabetic (blue bar), and nonspecific (non-VEGFR-
mediated) in-scV/Tc uptake in non-diabetic ApoE−/− mice (yellow
bar). (B) Average %ID/g for the same groups of mice, as calculated
from gamma well counting of harvested aorta. (C) Correlation for %ID
vs. %ID/g.
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the inner plaque area enriched in cells stained for en-
dothelial marker FVIII and macrophage marker Mac-3
(Figure 5). Quantitative immunohistochemistry of the aor-
tic tissue revealed greater expression of VEGFR-1 in thediabetic mice (9.17% ± 4.46%) compared with the non-
diabetic (1.88% ± 1.48%; P < 0.01). Similarly, VEGFR-2 ex-
pression was significantly higher in the diabetic mice
(3.25% ± 1.27%) compared with the non-diabetic (1.31% ±
0.86%; P < 0.01). Total macrophage burden in the athero-
sclerotic lesions of diabetic mice (5.85% ± 2.86%) was also
significantly higher compared with the non-diabetic mice
(0.99% ± 0.38%; P < 0.01). Immunofluorescence studies
showed co-localization of VEGFR-1 primarily with macro-
phage marker Mac3 and VEGFR-2 with endothelial cell
marker FVIII (Figure 6).
Discussion
This is the first study to report the results of in vivo
SPECT imaging of a 99mTc-labeled VEGFR-targeting mo-
lecular tracer (scV/Tc) to detect more advanced complex
lesions in diabetic ApoE−/−mice compared to age matched
non-diabetic ApoE−/− mice with fatty streaks. We showed
that the scV/Tc uptake is predominantly VEGFR-mediated
by showing significantly lower uptake of in-scV/Tc, inca-
pable of VEGFR binding.
According to the current models of plaque progression,
enhanced VEGF/VEGFR signaling plays an important role
in three critical processes leading to plaque vulnerability:
stimulation of angiogenesis in plaque, recruitment of mo-
nocytes into plaque, and increasing permeability of plaque
vasculature which leads to hemorrhage and inflammatory
cell extravasation [8,10]. Importantly, studies of acceler-
ated atherosclerosis and enhanced plaque vulnerability in
human diabetic patients, as well as in diabetic rabbit and
mouse atherosclerosis models, revealed higher prevalence
of VEGF and VEGFRs in diabetic vs. non-diabetic plaques
[15-17]. Immunohistochemical analysis confirmed that
the significantly higher uptake of the functionally active
scV/Tc in the more advanced and complex atherosclerotic
lesions in diabetic vs. non-diabetic ApoE−/− mice was due
to higher prevalence of both VEGFR-1 and VEGFR-2. Al-
though in this study, we did not image ApoE−/− mice fed
with high-fat (Western) diet to accelerate atherosclerosis
since the lesion histology in the diabetic mice is very
similar to that of mice at the same age fed with high-
fat (Western) diet [29].
Some variation in nonspecific uptake of the inactivated
in-scV/Tc tracer was noted among mice; however, the
level of uptake was significantly lower than receptor-
mediated uptake of scV/Tc. This small amount of non-
specific trapping of a protein-based tracer was probably
a result of the enhanced permeability and retention ef-
fects in inflammatory atherosclerotic tissue.
The diversity of VEGFR-expressing cells raises the
question which cells are responsible for scV/Tc uptake.
In agreement with other studies [10,14,28], our immu-
nohistochemical analysis indicates that in atherosclerotic
plaques, VEGFR-2 receptors in this ApoE−/− model are
Mac-3
VEGFR1
VEGFR2
FVIII
Diabetic ApoE-/- Non-diabetic ApoE-/-
20x
Figure 5 Immunohistochemical characterization of atherosclerotic plaques. Representative aortic tissue sections stained for VEGFR-1, VEGFR-2,
FVIII (marker for endothelial cells), and Mac-3 (marker for macrophages) in diabetic and non-diabetic ApoE−/− mice.
Macrophages VEGFR-1 Merge
Endothelial Cells VEGFR-2 Merge
200x
Figure 6 Differential expression of VEGFR-1 and VEGFR-2 on endothelial cells and macrophages. Double immunofluorescent staining for
VEGFRs and markers of endothelial cells (FVIII) and macrophages (Mac-3). Serial atherosclerotic sections from diabetic mice were double-stained
for VEGFR-1 and Mac-3 (upper row) or VEGFR-2 and FVIII (lower row), as indicated. Co-localization is visible on merged images as the yellow color.
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endothelial cells, while VEGFR-1 receptors are predom-
inantly expressed on intraplaque macrophages. In hu-
man atherosclerosis, endothelial cells are also found in
neoangiogenesis in the adventitia (vasa vasorum) and
media in coronary and carotid atherosclerotic plaques
associated with plaque vulnerability. These leaky capil-
laries express VEGR-2 on endothelial cells. The combined
binding of scV/Tc to both macrophages and endothelial
cells in plaque neoangiogenesis in theory provide two tar-
gets for scV/Tc binding to boost plaque signal [8,10,30].
Image analysis of VEGFR-1 and VEGFR-2 independently
in atherosclerotic plaques using tracers based on the
known VEGF mutants [31] with predominant affinity to
one receptor might further hone our ability to specifically
target neoangiogenesis.
Judging by the findings in mouse aortic aneurism
model [24], mouse graft arteriosclerosis model [25], and
mouse urine bladder inflammation model [26], a relatively
small (approximately 29 kDa) fluorescent scVEGF tracer
can be taken up not only by readily accessible luminal
endothelial cells but also by other VEGFR-expressing cells.
We expect that a similarly small (32 kDa) scV/Tc tracer is
also able to cross the vascular barrier and distribute be-
tween various VEGFR-expressing cells. In this respect, im-
aging with scV/Tc potentially provides more target cells
than ultrasound agents [23,28] or MRI agents (unpub-
lished data) that, due to their relatively large size, are con-
fined to the intravascular space targeting only VEGFRs on
luminal endothelial cells. Of note, quantitation of scV/Tc
uptake, either from scans or from gamma counting of tis-
sue samples, provides only the ‘average’ uptake values, and
do not reflect significant heterogeneity in VEGFR expres-
sion, as detected by immunohistochemical analysis of our
samples (Figures 5 and 6). Similar heterogeneity was ob-
served in harvested human plaques with a fluorescent
scVEGF-based tracer [28].
The uptake of 18 F-FDG in arterial vessel walls signa-
ling the high metabolic activity of inflammatory cells in
atherosclerotic plaque or vasculitis has been observed
and referenced extensively in the literature in both ani-
mal models and in patients [32]. The binding of scV/Tc
to VEGFR-1 expressed on macrophages indicates the si-
milar inflammation binding target as 18FDG. Differences
include the additional target of neoangiogenesis for scV/Tc
and the low constitutive expression of VEGFRs in normal
myocardium. Whether these differences will translate into
better specificity and signal to noise for scV/Tc vs. 18FDG
is yet to be determined.
The significance of our findings and, in general, the
interest in imaging VEGFRs in atherosclerotic plaques
are due to growing appreciation of the role of VEGF/
VEGFR signaling and enhanced VEGFR expression in ath-
erosclerosis [10] and in vulnerable plaque [8]. Our VEGFRimaging and immunohistochemical results comparing dia-
betic and non-diabetic ApoE−/− mice support the emer-
ging role of VEGFR as a biomarker for assessing complex
and inflamed atherosclerotic plaques.
Conclusion
We report the first in vivo imaging study of VEGFR
prevalence in atherosclerotic plaques in diabetic vs.
non-diabetic atherosclerosis-prone ApoE−/− mice, a model
where atherosclerosis is accelerated by diabetes. Using
scVEGF-PEG-DOTA/99mTc SPECT tracer (scV/Tc) that
binds to and is internalized by VEGFR-1 and VEGFR-2,
we found enhanced uptake of the tracer in atherosclerotic
plaques of diabetic vs. non-diabetic mice. The imaging
findings indicate higher prevalence of VEGFRs in acceler-
ated atherosclerosis and this conclusion is supported by
immunohistochemical analyses of VEGFRs in correspond-
ing plaques. Because higher prevalence of VEGFRs is as-
sociated with inflammation, angiogenesis, and enhanced
plaque vulnerability, our findings suggest that VEGFR im-
aging with scV/Tc may provide a clinically relevant bio-
marker of plaque vulnerability.
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